These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38554946)

  • 1. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer.
    van Driel PBAA; Boonstra MC; Slooter MD; Heukers R; Stammes MA; Snoeks TJA; de Bruijn HS; van Diest PJ; Vahrmeijer AL; van Bergen En Henegouwen PMP; van de Velde CJH; Löwik CWGM; Robinson DJ; Oliveira S
    J Control Release; 2016 May; 229():93-105. PubMed ID: 26988602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
    Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
    ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.
    van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study and evaluation of anti-EGFR nanobodies expressed in Pichia pastoris and Escherichia coli as antitumor moieties.
    Xi X; Sun W; Li H; Fan Q; Zhang X; Sun F
    Protein Expr Purif; 2021 Aug; 184():105888. PubMed ID: 33857600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
    Wang L; Zhang G; Qin L; Ye H; Wang Y; Long B; Jiao Z
    Recent Pat Anticancer Drug Discov; 2020; 15(3):200-211. PubMed ID: 32885759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival.
    Tabtimmai L; Suphakun P; Srisook P; Kiriwan D; Phanthong S; Kiatwuthinon P; Chaicumpa W; Choowongkomon K
    J Cell Biochem; 2019 Oct; 120(10):18077-18087. PubMed ID: 31172597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
    Xu L; Song X; Jia L
    Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector.
    Noor A; Walser G; Wesseling M; Giron P; Laffra AM; Haddouchi F; De Grève J; Kronenberger P
    BMC Res Notes; 2018 Oct; 11(1):751. PubMed ID: 30348204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and anti-EGFR nanobodies: review and update.
    Sharifi J; Khirehgesh MR; Safari F; Akbari B
    J Drug Target; 2021 Apr; 29(4):387-402. PubMed ID: 33210573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 18. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
    Zeronian MR; Doulkeridou S; van Bergen En Henegouwen PMP; Janssen BJC
    BMC Mol Cell Biol; 2022 Mar; 23(1):12. PubMed ID: 35232398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.
    Fan J; Zhuang X; Yang X; Xu Y; Zhou Z; Pan L; Chen S
    Signal Transduct Target Ther; 2021 Sep; 6(1):320. PubMed ID: 34475375
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.